Alex, Alexander A., <br/><br/>
Attrition in the pharmaceutical industry :  reasons, implications, and pathways forward / 
edited by Alexander A. Alex, C. John Harris, Dennis A. Smith. 
 - 1 online resource. 
<br/><br/> Includes index. 
<br/><br/>Attrition in drug discovery and development / Scott Boyer, Clive Brealey and Andrew M. Davis -- Compound attrition at the pre-clinical phase / Cornelis E.C.A. Hop -- Attrition in phase I / Dennis A. Smith and Thomas A. Baillie -- Compound attrition in phase II/III / Alexander Alex, C. John Harris, Wilma W. Keighley and Dennis A. Smith -- Post-marketing attrition / Dennis A. Smith -- Influence of the regulatory environment on attrition / Robert T. Clay -- Experimental screening strategies to reduce attrition risk / Marie-Claire Peakman, Matthew Troutman, Rose Gonzales and Anne Schmidt -- Medicinal chemistry strategies to prevent compound attrition / J. Richard Morphy -- Influence of phenotypic and target-based screening strategies on compound attrition and project choice / Andrew Bell, Wolfgang Fecke and Christine Williams -- In silico approaches to address compound attrition / Peter Gedeck, Christian Kramer, Richard Lewis -- Current and future strategies for improving drug discovery efficiency / Peter Mbugua Njogu and Kelly Chibale -- Impact of investment strategies, organizational structure and corporate environment on attrition, and future investment strategies to reduce attrition / Geoff Lawton. 
<br/><br/><label>ISBN: </label>9781118914342 (epub) 9781118819449 (pdf) 
<br/><br/><label>LCCN: </label>2015030480 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Pharmaceutical industry--Management.<br/>Pharmaceutical industry--Capital productivity.<br/>Industrial efficiency.<br/>Drug development.
<br/><br/><label>LC Class. No.: </label>HD9665.5 
<br/><br/><label>Dewey Class. No.: </label>615.1068/5 ALE